Membranoproliferative glomerulonephritis Medical Services in China

Membranoproliferative glomerulonephritis (MPGN) is a rare, chronic immune-mediated kidney disease characterized by histopathological changes including mesangial hypercellularity, thickening of the glomerular basement membrane, and duplication of the basement membrane ('double contours') visible on electron microscopy. Historically classified into types I, II (now termed dense deposit disease), and III, MPGN is now redefined based on underlying pathogenic mechanisms—primarily complement dysregulation (e.g., C3 nephropathy, autoantibodies against C3 convertase, or genetic mutations in complement regulators) or immune-complex deposition (often secondary to chronic infections like hepatitis C, autoimmune disorders such as SLE, or monoclonal gammopathies). The disease triggers inflammation and progressive injury to glomeruli, impairing filtration and leading to proteinuria, hematuria, hypertension, and declining glomerular filtration rate (GFR). Epidemiologically, MPGN accounts for <10% of primary glomerulonephritis cases in adults and is even rarer in children; incidence is estimated at 1–2 per million per year globally, with no strong gender predilection but a peak onset in adolescence and early adulthood. Risk factors include inherited complement pathway abnormalities (e.g., factor H, factor I, or MCP mutations), persistent viral infections (especially hepatitis C and less commonly HIV or EBV), autoimmune conditions (SLE, Sjögren’s syndrome), and lymphoproliferative disorders. Untreated or refractory MPGN carries high risk of progression to end-stage kidney disease (ESKD) within 10–15 years in up to 50% of patients. Quality of life is significantly impacted: patients often experience fatigue, edema-related discomfort, anxiety about renal decline, dietary and fluid restrictions, frequent clinic visits and lab monitoring, and psychosocial burden from long-term immunosuppression (e.g., corticosteroids, rituximab, eculizumab). Children may face growth delays and school absenteeism; adults report reduced work capacity, sexual dysfunction, and increased depression prevalence. Early diagnosis via kidney biopsy—including light, immunofluorescence, and electron microscopy—is critical, as treatment response varies substantially by etiology. Complement-targeted therapies have revolutionized management for primary C3-glomerulopathy–associated MPGN, while hepatitis C–related cases require antiviral therapy first. Despite advances, MPGN remains a challenging condition requiring multidisciplinary care involving nephrologists, immunologists, and pathologists to optimize outcomes and preserve kidney function.

Membranoproliferative glomerulonephritis (MPGN) is a rare, immune-mediated pattern of glomerular injury characterized histologically by mesangial hypercellularity, capillary wall thickening with double-contour ('tram-track') formation, and often complement activation. Historically classified into types I, II (dense deposit disease), and III, MPGN is now reclassified based on underlying pathogenic mechanisms—primarily dysregulation of the alternative complement pathway (aCP) or immune-complex–mediated injury. Common causes include chronic infections (e.g., hepatitis B and C virus, streptococcal endocarditis, subacute bacterial endocarditis, and less commonly HIV, syphilis, or Mycoplasma pneumoniae), monoclonal gammopathies (especially IgG or IgM paraproteins in Waldenström macroglobulinemia or multiple myeloma), autoimmune disorders (systemic lupus erythematosus, Sjögren syndrome, cryoglobulinemia), and malignancies (lymphoproliferative disorders, solid tumors). A significant proportion of cases are secondary to persistent antigenemia driving immune-complex deposition in the glomeruli, while others arise from uncontrolled complement activation due to autoantibodies (e.g., C3 nephritic factor—a stabilizer of the C3 convertase) or genetic deficiencies in complement regulatory proteins (e.g., factor H, factor I, membrane cofactor protein [CD46], or thrombomodulin). Triggers often involve acute or subacute immunologic insults: recurrent upper respiratory or skin infections may initiate immune-complex formation; viral reactivation (e.g., HBV or HCV) can induce cryoglobulin production or direct glomerular deposition; and surgical procedures or vaccinations—though rarely—may precipitate flares in predisposed individuals via molecular mimicry or bystander activation. Risk factors encompass both host and disease-related variables: age (peak incidence in adolescence and early adulthood for primary forms; older adults more commonly affected in secondary MPGN), male sex (slight male predominance observed in several cohorts), preexisting chronic kidney disease (CKD), hypertension, and proteinuria >1 g/day at diagnosis—all associated with accelerated progression to end-stage kidney disease (ESKD). Genetic factors play a pivotal role in complement-mediated MPGN: autosomal recessive or dominant mutations in CFH (complement factor H), CFI (complement factor I), CD46 (MCP), C3, or THBD (thrombomodulin) impair regulation of the alternative pathway, leading to chronic C3 cleavage, C3 fragment deposition, and glomerular inflammation. Additionally, polymorphisms in CFH (e.g., the Y402H variant) confer increased susceptibility, particularly when combined with environmental stressors. Environmental factors include endemic infections (e.g., schistosomiasis in endemic regions, which may trigger immune-complex MPGN), prolonged exposure to hydrocarbon solvents (historically linked to type I MPGN), and geographic variation in prevalence—suggesting interactions between local pathogen exposure and host genetics. Socioeconomic determinants such as limited access to timely diagnostics and antiviral therapy also indirectly increase risk of progression. Importantly, MPGN is not a single disease but a histopathologic response pattern; thus, identifying the precise etiology—via serologic testing (C3, C4, CH50, C3NeF, anti-FH antibodies), genetic screening, serum protein electrophoresis, viral serologies, and renal biopsy with immunofluorescence and electron microscopy—is essential for targeted therapy. Without accurate subclassification, patients may receive inappropriate immunosuppression or miss life-saving complement inhibition (e.g., eculizumab or ravulizumab in aCP-driven disease). Prognosis remains guarded: approximately 50% of untreated patients progress to ESKD within 10 years, underscoring the importance of early etiologic diagnosis and mechanism-specific intervention.

Membranoproliferative glomerulonephritis (MPGN) is a rare, immune-mediated pattern of glomerular injury characterized histologically by mesangial hypercellularity, double-contouring ("tram-tracking") of the glomerular basement membrane (GBM), and often subendothelial electron-dense deposits. It is not a single disease but a morphologic response to diverse underlying pathogenic mechanisms—traditionally classified into immune-complex–mediated (types I and III) and complement-mediated (type II, now termed C3 glomerulopathy) forms. Clinical presentation varies widely depending on disease chronicity, rate of progression, and predominant pathophysiologic driver. Early symptoms are frequently subtle or entirely absent; many patients are identified incidentally during routine urinalysis or evaluation for unexplained hypertension or edema. Microscopic hematuria—often persistent and dysmorphic—is typically the earliest urinary abnormality, reflecting glomerular capillary wall disruption. Mild proteinuria (<1 g/day) may accompany hematuria but is rarely prominent initially. Fatigue, mild lethargy, or nonspecific malaise may occur due to chronic inflammation or early reductions in glomerular filtration rate (GFR), though serum creatinine often remains normal in early stages. Hypertension may develop insidiously as renal perfusion autoregulation falters, particularly with progressive intraglomerular hypertension secondary to capillary loop narrowing and mesangial expansion.

Typical symptoms emerge as disease activity intensifies or chronicity accumulates. Nephrotic-range proteinuria (>3.5 g/day) occurs in approximately 30–50% of cases, especially in type I MPGN and some complement-driven variants, leading to hypoalbuminemia, peripheral edema (periorbital, lower extremity, or anasarca), and hyperlipidemia. Gross hematuria—often episodic and associated with upper respiratory infections—is less common than in IgA nephropathy but may occur, particularly during flares. Hypertension becomes more prevalent and often refractory, reflecting both volume overload and activation of the renin-angiotensin-aldosterone system (RAAS). Reduced GFR manifests as elevated serum creatinine and blood urea nitrogen (BUN), decreased estimated GFR (eGFR), and clinical signs of uremia—including anorexia, nausea, pruritus, and cognitive slowing—in advanced stages. Patients may report foamy urine due to significant proteinuria and decreased exercise tolerance secondary to anemia or fluid overload.

Accompanying symptoms reflect systemic associations and extra-renal manifestations. Approximately 20–30% of patients with immune-complex MPGN have underlying chronic infections (e.g., hepatitis B or C, endocarditis, chronic osteomyelitis) or autoimmune disorders (e.g., systemic lupus erythematosus [SLE], Sjögren syndrome, cryoglobulinemia), which may present with arthralgias, rash (e.g., purpura, malar), sicca symptoms, or constitutional fever. Complement-mediated MPGN (C3GN/Dense Deposit Disease) is strongly associated with dysregulation of the alternative complement pathway; patients may exhibit recurrent infections (especially encapsulated organisms), atypical hemolytic uremic syndrome (aHUS)-like episodes (microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injury), or inherited or acquired complement factor abnormalities (e.g., C3 nephritic factor, factor H/I autoantibodies). Some patients report livedo reticularis, digital ischemia, or ocular findings (e.g., drusen) reflecting systemic complement deposition. Chronic kidney disease–related symptoms such as nocturia, polyuria (in early tubulointerstitial involvement), and bone pain (due to secondary hyperparathyroidism) may appear with prolonged disease duration.

Complications arise from both primary glomerular injury and downstream consequences of chronic kidney disease. Progressive loss of renal function leads to end-stage kidney disease (ESKD) in ~50% of untreated patients within 10 years—higher in complement-mediated forms. Thromboembolic events (renal vein thrombosis, deep vein thrombosis, pulmonary embolism) occur with increased frequency in the nephrotic state due to urinary loss of antithrombin III, protein S, and plasminogen, coupled with hepatic synthesis of procoagulant factors. Infections—including spontaneous bacterial peritonitis, cellulitis, and pneumonia—are major causes of morbidity and mortality, exacerbated by immunosuppressive therapy and impaired opsonization. Cardiovascular complications—including left ventricular hypertrophy, heart failure, and accelerated atherosclerosis—are driven by hypertension, volume overload, dyslipidemia, and chronic inflammation. Metabolic bone disease, growth retardation in pediatric patients, and malnutrition secondary to protein loss and anorexia further contribute to long-term morbidity. Rarely, MPGN may evolve into crescentic glomerulonephritis or coexist with vasculitides, portending rapid deterioration.

Diagnosis requires integration of clinical, laboratory, serologic, and histopathologic data. Urinalysis reveals active sediment: dysmorphic red blood cells, red blood cell casts, and variable degrees of proteinuria. Serum studies include measurement of complement components: low C3 is nearly universal in MPGN (especially types I and II); low C4 suggests classical pathway activation (e.g., SLE, cryoglobulinemia); isolated C3 depression with normal C4 points toward alternative pathway dysregulation. C3 nephritic factor (C3NeF), anti-factor H antibodies, and genetic testing for complement regulatory proteins (CFH, CFI, CD46, C3, CFHR genes) are critical in suspected complement-mediated disease. Serum albumin, lipid panel, creatinine, eGFR, ANA, ANCA, hepatitis serologies, cryoglobulins, and serum/urine protein electrophoresis help identify secondary causes. Definitive diagnosis rests on renal biopsy: light microscopy shows lobular accentuation, mesangial hypercellularity, and GBM duplication; immunofluorescence demonstrates granular IgG/C3 deposits (immune-complex) or dominant C3 staining with scant/no immunoglobulin (complement-mediated); electron microscopy confirms subendothelial deposits (type I), intramembranous dense deposits (type II), or subepithelial/subendothelial deposits (type III). Repeat biopsy may be warranted to assess treatment response or evolving pathology.

Differential diagnosis includes other glomerulopathies with overlapping histologic features. IgA nephropathy and lupus nephritis (class V or IV+V) may show mesangial proliferation and GBM thickening but differ in immunofluorescence (predominant IgA vs. polyclonal IgG/C3 in lupus) and clinical context. Post-infectious GN typically presents acutely after streptococcal infection with transient hypocomplementemia and resolves spontaneously; biopsy shows endocapillary proliferation without tram-tracking. Cryoglobulinemic GN exhibits mixed cryoglobulinemia, palpable purpura, and characteristic 'fibrin thrombi' on EM. C3 glomerulopathy (C3GN and DDD) shares ultrastructural features with MPGN but lacks significant immunoglobulin deposition and is defined by isolated C3 activation. Thin basement membrane nephropathy and Alport syndrome lack mesangial proliferation and show different EM patterns (diffuse thinning or lamellation). Finally, thrombotic microangiopathies (e.g., aHUS, TTP) may mimic MPGN clinically but demonstrate schistocytes, thrombocytopenia, and absence of immune deposits on biopsy. Accurate classification guides targeted therapy—immunosuppression for immune-complex disease versus complement inhibition (e.g., eculizumab, ravulizumab, iptacopan) for complement-mediated forms—and prognostication.

Membranoproliferative glomerulonephritis (MPGN) is a rare, immune-mediated pattern of glomerular injury characterized by mesangial hypercellularity, double-contouring of the glomerular basement membrane ('tram-tracking'), and activation of the complement cascade—most commonly via the alternative or lectin pathways. Historically classified into types I, II (dense deposit disease), and III, MPGN is now reclassified based on underlying pathogenic mechanisms: immune-complex–mediated (e.g., secondary to chronic infections, autoimmune diseases, or monoclonal gammopathies) and complement-mediated (e.g., C3 glomerulopathy or autoantibody-driven dysregulation such as C3 nephritic factor). Accurate etiologic diagnosis—via comprehensive serologic testing (C3, C4, CH50, C3NeF, anti-FH antibodies), genetic screening (CFH, CFI, C3, MCP), and renal biopsy with immunofluorescence and electron microscopy—is essential before initiating therapy.

Conservative management forms the cornerstone of early intervention and remains critical across all disease stages. Blood pressure control targets systolic pressure <130 mmHg and diastolic <80 mmHg, achieved primarily with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), which confer dual antiproteinuric and renoprotective effects independent of blood pressure reduction. Dietary sodium restriction (<2 g/day) enhances efficacy of RAAS blockade and mitigates edema. Protein intake is moderated to 0.8–1.0 g/kg/day to reduce glomerular hyperfiltration without inducing malnutrition; in advanced chronic kidney disease (CKD), individualized adjustment per eGFR and nutritional status is mandatory. Lipid management follows KDIGO guidelines: statins are initiated for all patients with persistent proteinuria ≥1 g/day or CKD stage 3+, regardless of baseline LDL, given their pleiotropic anti-inflammatory and endothelial-stabilizing properties. Smoking cessation, vaccination (pneumococcal, influenza, hepatitis B), and avoidance of NSAIDs and nephrotoxic agents are rigorously enforced.

Pharmacotherapy is stratified by etiology and disease activity. For immune-complex–mediated MPGN, first-line treatment includes corticosteroids (e.g., oral prednisone 0.5–1 mg/kg/day tapered over 6 months) combined with cyclophosphamide (oral 1.5–2 mg/kg/day or IV pulse regimens) or mycophenolate mofetil (MMF) (750–1000 mg twice daily) in patients intolerant to alkylating agents. Rituximab (375 mg/m² weekly × 4 or 1000 mg × 2 doses two weeks apart) is increasingly preferred—particularly in post-infectious or autoimmune-associated cases—due to its favorable safety profile and robust B-cell depletion. In complement-mediated MPGN, especially C3 glomerulopathy with documented alternative pathway dysregulation, the monoclonal anti-C5 antibody eculizumab (900 mg IV weekly × 4, then 1200 mg every other week) demonstrates significant stabilization of eGFR and reduction in proteinuria in refractory cases, though cost and infection risk (notably Neisseria meningitidis) necessitate strict vaccination and antibiotic prophylaxis protocols. Emerging agents include ravulizumab (longer half-life C5 inhibitor), iptacopan (oral factor B inhibitor), and danicopan (factor D inhibitor), currently under evaluation in phase III trials. Plasma exchange may be considered acutely in rapidly progressive cases with crescent formation or severe complement activation, particularly when associated with thrombotic microangiopathy.

Surgical intervention has no primary role in MPGN management. However, nephrectomy may be indicated in rare instances of unilateral disease with uncontrollable hypertension or massive hematuria unresponsive to medical therapy—though this is exceedingly uncommon and not evidence-based for typical bilateral MPGN. More relevantly, surgical evaluation focuses on identifying and removing potential antigen sources: excision of chronic infected foci (e.g., dental abscesses, osteomyelitis), resection of lymphoproliferative malignancies (e.g., Waldenström macroglobulinemia), or removal of solid tumors associated with paraneoplastic immune-complex deposition. Liver transplantation is considered in select patients with hereditary complement factor deficiencies (e.g., CFH mutations) complicated by end-stage renal disease, though recurrence risk remains high without adjunctive complement inhibition.

China offers distinct advantages in MPGN care, anchored in integrated multidisciplinary infrastructure and rapid adoption of precision diagnostics. Major tertiary hospitals—including Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—house dedicated glomerular disease registries and perform routine next-generation sequencing for complement genes and mass spectrometry–based proteomic analysis of glomerular deposits, enabling molecular subtyping within 10–14 days. The National Medical Products Administration (NMPA) has expedited approval of eculizumab and rituximab, with subsidized access via the National Reimbursement Drug List since 2022. Furthermore, China leads globally in real-world evidence generation: the China Glomerulonephritis Registry (CGNR) has enrolled >12,000 biopsy-proven cases, informing region-specific treatment algorithms that emphasize early MMF-rituximab combinations for immune-complex disease and tiered complement inhibition strategies. Traditional Chinese Medicine (TCM) adjuncts—such as tripterygium glycosides (used cautiously with monitoring for hepatotoxicity and gonadal suppression) and astragalus-based formulations—are integrated under nephrologist supervision to ameliorate proteinuria and fatigue, supported by randomized controlled trials demonstrating additive antiproteinuric effects when combined with standard immunosuppression.

Recovery and long-term monitoring demand structured, patient-centered follow-up. Patients should undergo quarterly assessments including urinalysis, quantified urine protein-to-creatinine ratio, serum creatinine/eGFR, electrolytes, albumin, C3/C4, and complement functional assays (AP50/CH50). Renal biopsy repeat is recommended at 6–12 months in non-responders to assess histologic response and rule out evolving pathology (e.g., transition to crescentic GN). Lifestyle reinforcement includes supervised low-impact aerobic exercise (150 min/week), dietary counseling by certified renal dietitians, and psychosocial support to address depression/anxiety prevalence exceeding 30% in chronic GN populations. Pregnancy requires preconception counseling: conception is discouraged during active disease or immunosuppression; if pursued, close maternal-fetal surveillance and adjustment to pregnancy-safe agents (e.g., azathioprine instead of MMF, prednisone instead of mycophenolate) are mandatory. Ultimately, MPGN prognosis hinges on timely etiologic diagnosis, early complement or immune modulation, and sustained adherence to conservative measures—making coordinated, longitudinal nephrology care indispensable for preserving renal function and quality of life.